Gelonghui, January 30 | Recco Biotech (2179.HK) announced that its self-developed recombinant recombinant herpes zoster vaccine REC610 phase I clinical trial in China has completed the enrollment of the first batch of subjects. Using a randomized, double-blind, parallel-controlled design, the study recruited 180 healthy subjects aged 40 and above in Pu'er City, Yunnan Province to evaluate the safety, tolerability, and immunogenicity of REC610. According to the company's previous news, the product has completed head-to-head clinical studies with GSK Shingrix in the Philippines. The results show that REC610 is comparable to Shingrix in terms of cellular immunity and humoral immunity. In October 2023, China's CDE agreed to exempt REC610 from the Chinese Phase II clinical trial and approved the company to conduct phase I and phase III studies directly in China.
瑞科生物新佐剂重组带状疱疹疫苗中国I期临床研究完成首批受试者入组
Recco Biologics completes phase I clinical study of the new adjuvant recombinant shingles vaccine in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.